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RYSZARD B. KROL, MD 
Columbia, Missouri 
To determine whether survival after permanent ven•
tricular demand (VVI) pacing differs from survival after 
permanent dual chamber (DVI or DDD) pacing in pa•
tients with chronic high degree atrioventricular (AV) 
block (Mobitz type II or trifascicular block), 132 patients 
who received a VVI pacemaker (Group 1) and 48 pa•
tients who received a DVI or DDD pacemaker (Group 
2) were followed up for 1 to 5 years. There was no 
significant difference in sex distribution, mean age or 
incidence of coronary heart disease, hypertension, val•
vular heart disease, diabetes mellitus, stroke or renal 
failure between Groups 1 and 2. 
Overall, the predicted cumulative survival rate at 1, 
3 and 5 years was 89, 76 and 73%, respectively, for 
Group 1 and 95, 82 and 70%, respectively, for Group 
2. In patients with preexistent congestive heart failure, 
Before permanent cardiac pacemakers became available, 
patients with chronic Mobitz type II and complete trifas•
cicular atrioventricular (A V) block had a dismal prognosis. 
Nearly 50% died within 1 year and 75 to 90% died within 
5 years of the onset of these conduction disturbances (1-3). 
Those who lived were prone to frequent episodes of syn•
cope, presyncope, congestive heart failure and a variety of 
symptoms attributable to low cardiac output (3). Many stud-
From the Departments of Medicine and Surgery, University of Missouri 
Health Sciences Center and Harry S. Truman Memorial Veterans Hospital, 
Columbia, Missouri. 
Manuscript received August 29, 1985; revised manuscript received 
November 6, 1985, accepted November 19, 1985. 
Address for reprints: Martin A. Alpert, MD, Division of Cardiology, 
Room lE-65, University of Missouri Health Sciences Center, One Hospital 
Drive, Columbia, Missouri 65212 
© 1986 by the Amencan College of CardIology 
the predicted cumulative survival rate at 1, 3 and 5 years 
was 85,66 and 47%, respectively, for Group 1 (n = 53) 
and 94, 81 and 69%, respectively, for Group 2 (n = 
20). The 5 year predicted cumulative survival rate was 
significantly lower in Group 1 patients with preexistent 
congestive heart failure than in Group 2 patients with 
the same condition (p < 0.02). There was no significant 
difference in 5 year cumulative survival rate between 
Groups 1 and 2 for patients without preexistent conges•
tive heart failure. 
The results suggest that permanent dual chamber 
pacing enhances survival to a greater extent than does 
permanent ventricular demand pacing in patients with 
high degree A V block and preexistent congestive heart 
failure. 
(J Am Coli CardioI1986;7:925-32) 
ies (4-15) have demonstrated that permanent ventricular 
pacing has not only improved the quality of life of such 
individuals, but has also markedly improved survival, par•
ticularly in those with preexistent congestive heart failure. 
Dual chamber pacing theoretically offers comparative 
hemodynamic advantages over ventricular pacing because 
it preserves atrial transport function, thus maintaining car•
diac output at or near prebradyarrhythmic levels. Preser•
vation of atrial transport function may particularly benefit 
individuals with left ventricular dysfunction. Whether the 
hemodynamic advantages of dual chamber pacing translate 
into improved survival is uncertain. The objective of this 
study was to compare survival of patients with and without 
congestive heart failure who received a permanent ventric•
ular or dual chamber pacemaker for chronic Mobitz type II 
or trifascicular block. 
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Methods 
Patient selection. Patients were considered eligible for 
the study if they received a permanent cardiac pacemaker 
(VVI, DVI, DDD) for chronic persistent or intermittent high 
degree AV block. High degree AV block was defined as 
Mobitz type II A V block or trifascicular block (third degree 
A V block characterized by wide QRS complexes and a 
ventricular rate of less than 40 beats/min). Patients with 
acute or reversible precipitating causes, or both, for high 
degree A V block (including drugs, acute myocardial in•
farction and cardiac surgery) and patients who were not 
pacemaker-dependent after implantation were excluded from 
the study. Information was obtained by interview with and 
examination of patients, review of the medical records and 
consultation with referring physicians. 
Identification and classification of chronic coexistent 
illnesses. Congestive heart failure was defined in accord•
ance with the criteria for definite heart failure used by McKee 
et al. (16) in the Framingham study. Patients were included 
only if congestive heart failure had preceded the heart block 
(preexistent congestive heart failure). Criteria for coronary 
heart disease included definite angina pectoris or a history 
of myocardial infarction confirmed by serum cardiac en•
zyme elevation or characteristic electrocardiographic ab•
normalities. Systemic hypertension was diagnosed when blood 
pressure exceeded 140/90 mm Hg on three consecutive out•
patient visits. Congenital heart disease and dilated cardio•
myopathy were confirmed by cardiac catheterization. Val-
Table 1. Patient Characteristics 
All Patients 
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vular heart disease was diagnosed by echocardiography or 
cardiac catheterization. Patients with no evidence of organic 
heart disease were classified as having conduction system 
disease only. Diabetes mellitus was diagnosed on the basis 
of an elevated fasting blood sugar level. 
Patient characteristics. The study group consisted of 
180 patients; 132 with a permanent ventricular demand pace•
maker (VVI) (Group 1) and 48 with a permanent dual cham•
ber pacemaker (36 with DVI and 12 with DDD) (Group 2). 
Patient characteristics were analyzed for the entire study 
group and for the subgroups with preexistent congestive 
heart failure. Sex distribution, mean age and presenting 
arrhythmias are shown in Table 1. The nature and distri•
bution of chronic coexistent illnesses are summarized in 
Table 2. Table 3 lists the therapeutic modalities used to treat 
the major chronic coexistent illnesses. 
Follow-up. The follow-up period for Group 1 began on 
January 1,1966 and ended on December 31,1984; that for 
Group 2 began on January 4, 1979 and ended on December 
31, 1984. Total follow-up time ranged from 1 to 18 years 
for Group 1 and from 1 to 5 years for Group 2. Group 1 
and Group 2 patients who were lost to follow-up remained 
in the study until the time of their last clinic visit. Follow•
up information was obtained by review of medical records, 
patient interviews and examination, discussions with fam•
ilies and consultation with referring physicians. 
Pacemaker information. Pulse generators and pace•
maker electrodes in Group 1 patients were manufactured by 
Medtronic Inc. in 106 cases, Cordis Inc. in 14 cases and 
Patients With CHF 
Ventricular Dual Chamber Ventricular Dual Chamber 
Patient Characteristics Paced (Group I) Paced (Group 2) Paced (Group I) Paced (Group 2) 
No. of patients 132 48 53 20 
Men 75 32 31 12 
Women 57 16 22 8 
Mean age (yr) 67 ± 6 69 ± 6 68 ± 5 68 ± 6 
Presenting arrhythmia 
Mobitz type II A V block 35 II 9 5 
Trifascicular block 118 46 49 17 
Both* 21 9 5 2 
Presenting symptoms 
Lassitude/weakness 93 35 39 13 
Dyspnea on exertion 71 25 44 14 
Pre-syncope 48 16 18 6 
Syncope 45 16 19 9 
Altered sensorium 20 9 10 4 
Palpitation 9 2 3 I 
Angina pectoris 5 2 
Seizures 3 0 0 0 
No symptoms 14 5 0 0 
*Refers to patients who demonstrated both trifascicular and Mobitz type II A V block at various times during 
the monitoring period. A V = atrioventricular; CHF = preexistent congestive heart failure. 
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Table 2. Chronic Coexistent Illnesses 
ALPERT ET AL. 927 
SURVIVAL AFTER PERMANENT PACEMAKER IMPLANTATION 
All Patients Patients With CHF 
Ventncular 
Coexistent Illness Paced (n = 132) 
Conduction system 49(37) 
disease only 
Congestive heart failure 53(40) 
Coronary artery disease 40(30) 
Diabetes mellitus 32(24) 
Hypertension 17(13) 
Valvular heart disease 12(9)* 
Cerebral infarctlon 7(5) 
Cancer 6(4) 
Dilated cardiomyopathy 4(3) 
Emphysema 4(3) 
Renal failure 3(2) 
ArteriosclerosIs obliterans 3(2) 
Hypothyroidism 3(2):1: 
Atrial septal defect 2(2) 
Syphilis I( I) 
ParkinSOnism I( I) 
Tuberculosis I( I) 
Dual Chamber 
Paced (n = 48) 
18(38) 
20(42) 
20(42) 
12(25) 
8(16) 
5(10)t 
2(4) 
1(2) 
1(2) 
3(6) 
0(0) 
2(4) 
1(2):1: 
0(0) 
0(0) 
0(0) 
0(0) 
Ventricular 
Paced (n = 53) 
28(53) 
\0(19) 
8(15) 
7(13) 
1(2) 
1(2) 
4(8) 
1(2) 
3(6) 
2(4) 
1(2) 
0(0) 
0(0) 
0(0) 
0(0) 
Dual Chamber 
Paced (n = 20) 
9(43) 
6(30) 
3(15) 
1(5) 
1(5) 
1(5) 
1(5) 
1(5) 
0(0) 
1(5) 
0(0) 
0(0) 
0(0) 
0(0) 
0(0) 
* Seven with aortic stenosis, four with mitral regurgitation, one with mitral stenosis and two with previous 
valve replacement; t four with aortic stenosis, one with mitral regurgitation; :j: euthyroid when studied. Numbers 
in parentheses signify percent of group or subgroup. CHF = congestive heart failure. 
Starr-Edwards Inc, in 12 cases. Pulse generators and elec•
trodes in Group 2 patients were manufactured by Medtronic 
Inc. in all cases. 
Statistical analysis. Survival curves were derived using 
methods described by Gehan (17). Breslow's generalized 
Kruskal-Wallis test (18) was used to determine whether 
there were differences in predicted cumulative survival be•
tween subgroups. Survival data were analyzed for the first 
5 years of follow-up in Groups 1 and 2 to permit valid 
comparison of data. The chi-square test was used to deter•
mine whether differences in the incidence of presenting 
arrhythmias, presenting symptoms or chronic coexistent ill•
nesses between Groups 1 and 2 were significant. A prob•
ability (p) value of less than 0.05 was considered necessary 
for statistical significance. 
Results 
Overall survival. Predicted cumulative survival rates 
for years 1 through 5 for Groups 1 and 2 are shown in Table 
4 and Figure 1. There was no significant difference in overall 
5 year predicted cumulative survival rates between the two 
groups. 
Survival in patients with and without preexistent 
congestive heart failure. Predicted cumulative survival rates 
for years 1 through 5 for patients in Groups 1 and 2 with 
preexistent congestive heart failure are shown in Table 4. 
Survival curves for patients in Groups 1 and 2 with and 
without preexistent congestive heart failure are shown in 
Figures 2 and 3. 
In Group 1, the 5 year predicted cumulative survival rate 
was significantly lower in patients with than in patients 
without preexistent congestive heart failure (p < 0.005)(Fig. 
2). There was no significant difference in the 5 year pre•
dicted cumulative survival rates between patients with and 
without congestive heart failure in Group 2 (Fig. 3). The 
predicted cumulative survival rate at 5 years was signifi•
cantly higher in Group 2 patients with preexistent congestive 
heart failure than in Group 1 patients with preexistent failure 
(p < 0.02) (Fig. 4). There was no significant difference in 
predicted cumulative survival rates for patients without pre•
existent congestive heart failure between Groups 1 and 2. 
Causes of congestive heart failure. Causes of conges•
tive heart failure in Group 1 patients were coronary artery 
disease in 28, hypertension in 11, valvular heart disease in 
7, dilated cardiomyopathy in 4 and renal failure in 3 patients. 
Causes of congestive heart failure in Group 2 patients were 
coronary artery disease in 12, hypertension in 4, valvular 
heart disease in 3 and dilated cardiomyopathy in 1 patient. 
Impact of other chronic coexistent illnesses on sur•
vival. Predicted cumulative survival rates for years 1 through 
5 for patients with coronary artery disease, hypertension, 
valvular heart disease and diabetes mellitus in Groups 1 and 
2 are shown in Table 4. Other chronic coexistent illnesses 
occurred with insufficient frequency (Table 2) to calculate 
meaningful survival data. There were no significant differ-
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Table 3. Therapeutic Modalities Used to Treat Major Chronic Coexistent Illnesses 
Ventricular Paced Dual Chamber Paced 
All Patients Patients With CHF All Patients Patients With CHF 
Therapy (n= 132) (n=53) (n=48) (n=20) 
Medical 
Nitrate 39(30) 26(49) 18(38) 9(45) 
Beta-adrenergic 31(23) 0(0) 14(29) 0(0) 
blocking drug 
Calcium channel 4(3) 2(4) 5(10) 4(20) 
antagonist 
Digitalis 51(39) 51(100) 20(42) 20(100) 
Diuretic 52(39) 48(90) 23(48) 20(100) 
Arteriolar dilator 5(4) 2(4) 6(12) 4(20) 
Sympatholytic drug 5(4) 2(4) 4(8) 2(10) 
Insulin 22(17) 4(8) 8(\7) 2(10) 
Oral hypoglycemic drug 8(6) 2(4) 2(4) 1(5) 
Antineoplastic drug 6(4) 0(0) 1(2) 0(0) 
Adrenal corticosteroid 2(2) 0(0) 0(0) 0(0) 
Bronchodilator 4(3) 1(2) 3(6) 1(5) 
Sympathomimetic drug 2(2) 1(2) 1(2) 0(0) 
Thyroid supplement 3(2) 1(2) 0(0) 1(5) 
Surgical/mechanical 
Coronary artery 5(4) 1(2) 3(6) 0(0) 
bypass surgery 
Heart valve 2(2) 2(4) 1(2) 1(5) 
replacement 
Hemodialysis 2(2) 2(4) 0(0) 0(0) 
Radiation therapy 1(1) 0(0) 0(0) 0(0) 
There were no significant differences between ventricular (Group I) and dual chamber (Group 2) paced 
patients for any therapeutic modality either for all patients or for patients with congestive heart failure (CHF). 
Numbers in parentheses signify percent of group or subgroup. 
ences in predicted cumulative 5 year survival rates between 
Groups 1 and 2 for patients with and without coronary artery 
disease, hypertension, valvular heart disease and diabetes 
mellitus. Of the 40 Group I patients with coronary artery 
disease, 13 had hypertension and 10 had diabetes mellitus. 
Of the 20 Group 2 patients with coronary artery disease, 5 
had hypertension and 4 had diabetes mellitus. 
Group 1 patients with isolated conduction system disease 
demonstrated significantly higher 5 year predicted cumu•
lative survival rates than those in Group 1 with associated 
coronary artery disease (p < 0.01), hypertension (p < 0.025) 
or diabetes mellitus (p < 0.025) (Table 4). All Group 2 
patients with isolated conduction system disease survived 
the follow-up period, thus precluding calculation of pre•
dicted cumulative survival and preventing valid comparison 
with other subgroups using the Kruskal-Wallis test (Table 
4). 
Mortality and causes of death. Mortality data and cause 
of death in Groups I and 2 are summarized in Table 5. 
Impact of sex and age at implantation on sur•
vival. Table 4 shows the predicted cumulative survival rates 
for years 1 through 5 for Groups I and 2, for men and 
women and for patients less than 66 years old, 66 to 74 
years old and 75 years old or more at the time of pacemaker 
implantation. There were no significant differences in pre•
dicted cumulative survival between men and women in either 
group. Survival rates tended to decrease with increasing age, 
but the differences between groups were not statistically 
significant. 
Discussion 
Prognosis after permanent ventricular pacing. The 
prognosis of patients with untreated high degree A V block 
is grim. Reported survival rates at I year approach 50% and 
range from 10 to 33% at 5 years (1-3). Substantially higher 
survival rates have been reported after permanent ventricular 
pacemaker implantation, ranging from 81 to 93% at I year 
and 48 to 66% at 5 years (4-15). Although there is some 
variation in reported survival rates, virtually all studies as•
sessing the prognosis of patients with high degree A V block 
after permanent ventricular pacemaker implantation have 
demonstrated that survival is closely related to the nature 
and severity of the underlying organic heart disease, pri•
marily coronary artery disease and its complications (4-15). 
JACC Vol 7. No.4 
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Table 4. Survival Data 
Mean Age 
Variable n (yr) 
All patients 
Ventricular 132 67 ± 6 
Dual chamber 48 69 ± 6 
Men 
Ventricular 75 67 ± 6 
Dual chamber 32 69 ± 6 
Women 
Ventricular 57 68 ± 7 
Dual chamber 16 69 ± 7 
< 66 years old 
Ventricular 35 
Dual chamber II 
66 to 74 years old 
Ventricular 43 
Dual chamber 16 
2:: 75 years old 
Ventricular 54 
Dual chamber 21 
Mobitz type II 
AV block 
Ventricular 35 67 ± 6 
Dual chamber II 69 ± 6 
Trifascicular block 
VentrIcular 118 67 ± 6 
Dual chamber 49 69 ± 6 
Conduction system 
disease only 
Ventricular 49 67 ± 6 
Dual chamber 18 69 ± 5 
Congestive heart 
failure 
VentrIcular 53 67 ± 5 
Dual chamber 20 68 ± 6 
Coronary artery 
disease 
Ventricular 40 68 ± 6 
Dual chamber 20 69 ± 6 
Hypertension 
Ventricular 17 68 ± 7 
Dual chamber 8 66 ± 9 
Va\ vular heart 
disease 
Ventricular 12 65 ± 10 
Dual chamber 5 68 ± 8 
Diabetes mellitus 
Ventricular 32 67 ± 6 
Dual chamber 12 69 ± 8 
AV = atrioventricular; n = number of patients. 
Impact of preexistent congestive heart failure on sur•
vival after permanent ventricular pacing. Several recent 
studies (13,15) have reported results that underscore the 
negative impact of preexistent congestive heart failure on 
survival after permanent ventricular pacemaker implanta•
tion. Simon and Janz (15) reported a survival rate of 87, 
68 and 55%, respectively, at 1, 3 and 5 years for patients 
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Predicted Cumulative Survival (%) 
I yr 2 yr 3 yr 4 yr 5 yr 
89 82 76 69 63 
95 88 82 76 70 
89 82 76 69 63 
95 88 82 75 69 
90 83 77 70 64 
94 89 83 78 72 
90 84 78 71 65 
98 92 86 80 74 
87 80 74 68 62 
96 91 85 79 74 
92 84 77 69 61 
92 85 79 72 65 
88 81 75 69 63 
95 88 82 76 70 
89 92 76 69 63 
95 88 82 76 70 
93 90 86 83 80 
85 76 66 56 47 
94 87 81 74 69 
88 78 69 59 50 
90 83 76 69 62 
89 82 76 69 63 
92 87 81 76 70 
80 76 72 68 64 
96 88 80 72 65 
92 86 80 74 68 
with high degree A V block and preexistent congestive heart 
failure, and a survival rate of 89, 77 and 66%, respectively, 
at 1, 3 and 5 years for patients without preexistent congestive 
heart failure. These differences were not statistically sig•
nificant. Laczkovics et al. (19) reported a 50% mortality 
rate at 3 years and Castberg (20) reported a 50% mortality 
rate at 4 years for patients with congestive heart failure who 
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Figure 1. Overall predicted cumulative survival. There was no 
significant difference in overall 5 year predicted cumulative sur•
vival rates between Group I (ventricular paced) and Group 2 (dual 
chamber paced). 
received a permanent pacemaker for high degree A V block. 
In our study, the predicted cumulative survival rate at 5 
years for patients with preexistent congestive heart failure 
(47%) was significantly lower than that of patients without 
preexistent failure (73%, p < 0.005). Thus, our results 
confirm the negative impact of preexistent congestive heart 
failure on survival after permanent ventricular pacemaker 
implantation for high degree A V block. 
Hemodynamic advantages of dual chamber pacing 
over ventricular pacing. Dual chamber pacing has been 
shown to possess comparative hemodynamic advantages over 
Figure 2. Predicted cumulative survival rates of ventricular paced 
patients (Group 1) with and without preexistent congestive heart 
failure (CHF). The 5 year predicted cumulative survival rate was 
significantly higher in patients without preexistent congestive heart 
failure (non-CHF) than in those with preexistent congestive heart 
failure (p < 0.005). 
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5 
Years Following Pacemaker Implantation 
Figure 3. Predicted cumulative survival rates of dual chamber 
paced patients (Group 2) with and without congestive heart failure. 
There was no significant difference in the 5 year predicted cu•
mulative survival rates between groups with and without preex•
istent congestive heart failure (CHF) in patients receiving a per•
manent dual chamber pacemaker. 
ventricular pacing during acute myocardial infarction (21) 
and in patients recovering from cardiac surgery (22). Recent 
studies (23-30) have demonstrated that patients receiving a 
permanent dual chamber pacemaker may derive similar 
hemodynamic benefits. which accrue from properly timed 
atrial contraction. With ventricular pacing. atrial contraction 
enhances ventricular filling intermittently (with A V disso•
ciation) or not at all (with 1:1 ventriculoatrial conduction). 
The resultant loss of atrial transport function is particularly 
Figure 4. Predicted cumulative survival rates of patients with 
preexistent congestive heart failure who received either a perma•
nent ventricular or dual chamber pacemaker. The 5 year predicted 
cumulative survival rate of patients with a permanent dual chamber 
pacemaker was significantly higher than that of patients with a 
permanent ventricular pacemaker (p < 0.02). 
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Table 5. Causes of Death 
Ventricular Paced 
Cause of Death (Group I) 
Total 132 
Total dead 45 
Cause of death known 40 
Acute myocardial IS 
infarction 
Congestive heart 13 
failure 
Cancer 4 
Pneumonia 2 
Stroke 2 
Pulmonary emboli 2 
Emphysema/chronic 
bronchitis 
Renal failure I 
Cause of death unknown 5 
Sudden; pacemaker 
function normal 
Sudden; pacemaker 2 
function unknown 
Nonsudden 2 
Dual Chamber Paced 
(Group 2) 
48 
7 
7 
3 
o 
o 
o 
I 
o 
o 
o 
o 
likely to impair cardiac performance in patients with preex•
istent left ventricular dysfunction. Properly timed atrial or 
dual chamber pacing restores atrial transport function, re•
sulting in improved cardiac performance (23-30). Using 
data obtained during ventricular pacing as a baseline, Stew•
art et al. (31) demonstrated that dual chamber pacing produced 
an average overall increase of 19% in cardiac output (mea•
sured using continuous wave Doppler recording) and a 30% 
increase in patients with 1: 1 ventriculoatrial VVI pacing. 
Ditsch et al. (32) observed a 53.5% rise in cardiac index 
and a 7.5% decrease in left ventricular end-diastolic volume 
in 16 patients with normal systolic left ventricular function 
at rest during the transition from VVI to DDD pacing. Reiter 
and Hindman (33) studied seven patients with depressed left 
ventricular ejection fraction (mean 29%) and New York 
Heart Association functional class III or IV congestive heart 
failure. Cardiac index was higher in all patients at heart 
rates of 75 to 100 beats/min with A V sequential pacing 
compared with VVI pacing. The mean improvement in car•
diac index was 17% at a heart rate of 75 beats/min, 23% 
at a rate of 85 beats/min and 29% at a rate of 100 beats/min. 
A recent study by DiCola et al. (34) demonstrated greater 
exercise tolerance with dual chamber pacing than with ven•
tricular pacing, suggesting that the comparative hemody•
namic benefits of dual chamber pacing might result in clin•
ical benefits. 
Comparative survival after permanent ventricular and 
dual chamber pacing in patients with and without preex•
istent congestive heart failure. Our study is the first to 
compare survival characteristics of patients with chronic 
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high degree A V block receiving a permanent ventricular 
pacemaker with those of patients receiving a dual chamber 
pacemaker for chronic high degree A V block. It is also the 
first study to explore the comparative impact of congestive 
heart failure on survival in these two groups. Our results 
show that permanent dual chamber pacing (Group 2) en•
hances survival (relative to permanent ventricular pacing, 
Group I) in patients with chronic high degree A V block 
and preexistent congestive heart failure, but not in patients 
without preexistent failure. There were no significant dif•
ferences in predicted cumulative survival rates between Groups 
1 and 2 for patients with potential underlying causes of 
congestive heart failure (hypertension, coronary artery dis•
ease, valvular heart disease). This suggests that enhanced 
survival in Group 2 may be the result of the comparative 
hemodynamic advantages of dual chamber pacing. 
Limitations. Our conclusions should be interpreted in 
light of certain limitations imposed by the study design. 
Because this study was retrospective, we were forced in 
many cases to rely on clinical information obtained by phy•
sicians other than those directly involved in the study. In 
particular, left ventricular function was not routinely mea•
sured. This limitation may have influenced our ability to 
accurately diagnose left ventricular dysfunction and cer•
tainly impaired our ability to gauge its severity. To counter 
this, we required patients to demonstrate criteria for definite 
heart failure as delineated in the Framingham study for 
inclusion in the congestive heart failure subgroups. Com•
parison of subgroups in a retrospective study is hazardous 
because of the potential dissimilarity of patient character•
istics and treatment modalities between groups. As shown 
in Tables 1 to 3, the patient characteristics and incidence 
of coexistent illnesses in Groups 1 and 2 were similar (the 
incidence of coronary artery disease, however, was actually 
higher in the dual chamber paced group than in the ven•
tricular paced group). Moreover, there was no significant 
difference between the two groups in the frequency of use 
of medical or surgical treatment modalities for the most 
common coexistent illnesses (Table 4). This suggests that 
Groups 1 and 2 were comparable (although not matched) 
despite the long interval of time permitted for entry of patients. 
Conclusion. Despite the potential limitations of this study, 
we believe the results suggest that permanent dual chamber 
pacing enhances survival to a greater extent than does per•
manent ventricular pacing in patients with chronic high de•
gree A V block and preexistent congestive heart failure. 
We thank Cindy Branson for secretarial assistance and Rebecca J. Morgan, 
RN for technical assistance. 
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